J. Wu

发表

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

J. Ware, J. Spoerke, P. Workman, 2014, Clinical Cancer Research.

Phase I Study of Sequence-Selective Minor Groove DNA Binding Agent SJG-136 in Patients with Advanced Solid Tumors

R. Begent, P. Loadman, D. Hochhauser, 2009, Clinical Cancer Research.

Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study.

J. Sosman, F. Hodi, S. Gettinger, 2013 .

Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors

P. Hegde, P. LoRusso, A. Patnaik, 2012, Clinical Cancer Research.

Cancer Therapy : Clinical Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP 1 , a Novel Antiangiogenesis Agent , in Two Phase I Trials in Patients with Advanced Solid Tumors

P. Hegde, P. LoRusso, A. Patnaik, 2012 .

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.

T. Kipps, A. Langerak, A. Kater, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract B153: A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamic (PD) activity of the dual PI3K/mTOR inhibitor GDC-0980 administered once weekly (QW).

G. Jayson, J. Ware, J. Soria, 2011 .

Cancer Therapy : Clinical gH 2 AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents : Results from 2 Phase I Clinical Trials of SJG-136 ( SG 2000 )

John A. Hartley, Tim Meyer, Daniel Hochhauser, 2013 .

γ-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000)

Tim Meyer, Daniel Hochhauser, I. Puzanov, 2012, Clinical Cancer Research.

Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068

G. Hampton, J. Baselga, J. Tabernero, 2013, Clinical Cancer Research.

Treatment with Gefitinib or Lapatinib Induces Drug Resistance through Downregulation of Topoisomerase IIα Expression

A. Makris, D. Hochhauser, J. Hartley, 2013, Molecular Cancer Therapeutics.

DOWNREGULATION OF TOPOISOMERASE IIα EXPRESSION

A. Makris, D. Hochhauser, J. Hartley, 2013 .

Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

U. Jaeger, T. Kipps, A. Kater, 2020 .

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

U. Jaeger, T. Kipps, A. Kater, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tigit, CD226 and PD-L1/PD-1 Are Highly Expressed By Marrow-Infiltrating T Cells in Patients with Multiple Myeloma

Connie Y. C. Ma, R. Meng, J. Grogan, 2016 .

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

T. Kipps, A. Langerak, A. Kater, 2019, Blood.

Phase I Study of Sequence-Selective Minor Groove DNA Binding Agent SJG-136 in Patients with Advanced Solid Tumors

R. Begent, P. Loadman, D. Hochhauser, 2009, Clinical Cancer Research.

Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068

G. Hampton, J. Baselga, J. Tabernero, 2013, Clinical Cancer Research.